Search
Dexchlorpheniramine
go.drugbank.com/drugs/DB13679InvestigationalDexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic react...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecu...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesLanepitant
go.drugbank.com/drugs/DB19599ExperimentalThe usage of the INN stem '-pitant' in the name indicates that Lanepitant is a neurokinin NK1 (substance P) receptor antagonist. Lanepitant has a monoisotopic molecular weight of 559.35 Da.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigationalMilsaperidone is an atypical antipsychotic agent that rapidly interconverts to iloperidone in vivo. Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. Similarly, milsaperidone acts ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNafimidone
go.drugbank.com/drugs/DB20780ExperimentalNafimidone is a small molecule drug. Nafimidone has a monoisotopic molecular weight of 236.09 Da.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsClofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnClofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye -...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesHydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Althou...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsVoriconazole
go.drugbank.com/drugs/DB00582ApprovedInvestigationalVoriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasiv...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsHeparin
go.drugbank.com/drugs/DB01109ApprovedInvestigationalUnfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibl...
Products: Hep-Lock U/P, EPARINA CALCICA MYLAN GENERICSCarvedilol
go.drugbank.com/drugs/DB01136ApprovedInvestigationalCarvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunct...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: CARVEDILOLO DOC GENERICI, CARVEDILOLO MYLAN GENERICS